GIKLY
Price
$4.77
Change
-$0.01 (-0.21%)
Updated
Apr 24 closing price
Capitalization
8.78B
14 days until earnings call
GRFS
Price
$7.14
Change
-$0.07 (-0.97%)
Updated
Apr 28, 04:59 PM (EDT)
Capitalization
5.48B
14 days until earnings call
Ad is loading...

GIKLY vs GRFS

Header iconGIKLY vs GRFS Comparison
Open Charts GIKLY vs GRFSBanner chart's image
Grifols Sa
Price$4.77
Change-$0.01 (-0.21%)
Volume$138
Capitalization8.78B
Grifols SA
Price$7.14
Change-$0.07 (-0.97%)
Volume$3.84K
Capitalization5.48B
GIKLY vs GRFS Comparison Chart
Loading...
GRFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GIKLY vs. GRFS commentary
Apr 29, 2025

To understand the difference between Grifols SA - ADR (GIKLY) vs. Grifols SA - ADR - Level III (GRFS) it is enough to know the definitions of ADR and ADR - Level III

ADR - American depositary receipt (ADR) is a certificate issued by a U.S. depositary bank representing a specified number of shares (often 1 share) of a foreign company's stock. ADRs are denominated in U.S. dollars and trade on U.S. stock markets and OTC depending on the ADRs classification.

ADR - Level III - American depositary receipt (ADR) is a certificate issued by a U.S. depositary bank representing a specified number of shares (often 1 share) of a foreign company's stock. ADRs are denominated in U.S. dollars. Foreign companies issuing Level-III ADRs are mandated to fulfill all registration and reporting requirements imposed by the SEC. The security is allowed to be listed on a major U.S. stock exchange such as the New York Stock Exchange or the Nasdaq Stock Market. Unlike other types of ADR, Level-III ADRs can raise capital through a public offering within the United State.

Ad is loading...
COMPARISON
Comparison
Apr 29, 2025
Stock price -- (GIKLY: $4.77 vs. GRFS: $7.21)
Brand notoriety: GIKLY and GRFS are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: GIKLY: 14% vs. GRFS: 85%
Market capitalization -- GIKLY: $8.78B vs. GRFS: $5.48B
GIKLY [@Pharmaceuticals: Major] is valued at $8.78B. GRFS’s [@Pharmaceuticals: Major] market capitalization is $5.48B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GIKLY’s FA Score shows that 0 FA rating(s) are green whileGRFS’s FA Score has 0 green FA rating(s).

  • GIKLY’s FA Score: 0 green, 5 red.
  • GRFS’s FA Score: 0 green, 5 red.
According to our system of comparison, both GIKLY and GRFS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GRFS’s TA Score shows that 5 TA indicator(s) are bullish.

  • GRFS’s TA Score: 5 bullish, 5 bearish.

Price Growth

GIKLY (@Pharmaceuticals: Major) experienced а +5.76% price change this week, while GRFS (@Pharmaceuticals: Major) price change was +1.84% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +4.86%. For the same industry, the average monthly price growth was -1.19%, and the average quarterly price growth was -8.11%.

Reported Earning Dates

GIKLY is expected to report earnings on Jul 24, 2025.

GRFS is expected to report earnings on Jul 24, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+4.86% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GIKLY($8.79B) has a higher market cap than GRFS($5.48B). GIKLY has higher P/E ratio than GRFS: GIKLY (75.19) vs GRFS (68.68). GIKLY YTD gains are higher at: 1.489 vs. GRFS (-3.091). GIKLY has higher annual earnings (EBITDA): 726M vs. GRFS (640M). GIKLY (557M) and GRFS (544M) have equal amount of cash in the bank . GIKLY (10.9B) and GRFS (11.1B) have identical debt. GRFS (6.54B) and GIKLY (6.46B) have equivalent revenues.
GIKLYGRFSGIKLY / GRFS
Capitalization8.79B5.48B160%
EBITDA726M640M113%
Gain YTD1.489-3.091-48%
P/E Ratio75.1968.68109%
Revenue6.46B6.54B99%
Total Cash557M544M102%
Total Debt10.9B11.1B98%
FUNDAMENTALS RATINGS
GIKLY vs GRFS: Fundamental Ratings
GIKLY
GRFS
OUTLOOK RATING
1..100
5018
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
50
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8787
PRICE GROWTH RATING
1..100
5456
P/E GROWTH RATING
1..100
9696
SEASONALITY SCORE
1..100
7585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GIKLY's Valuation (50) in the null industry is in the same range as GRFS (50) in the Pharmaceuticals Major industry. This means that GIKLY’s stock grew similarly to GRFS’s over the last 12 months.

GIKLY's Profit vs Risk Rating (100) in the null industry is in the same range as GRFS (100) in the Pharmaceuticals Major industry. This means that GIKLY’s stock grew similarly to GRFS’s over the last 12 months.

GIKLY's SMR Rating (87) in the null industry is in the same range as GRFS (87) in the Pharmaceuticals Major industry. This means that GIKLY’s stock grew similarly to GRFS’s over the last 12 months.

GIKLY's Price Growth Rating (54) in the null industry is in the same range as GRFS (56) in the Pharmaceuticals Major industry. This means that GIKLY’s stock grew similarly to GRFS’s over the last 12 months.

GIKLY's P/E Growth Rating (96) in the null industry is in the same range as GRFS (96) in the Pharmaceuticals Major industry. This means that GIKLY’s stock grew similarly to GRFS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GRFS
RSI
ODDS (%)
Bullish Trend 4 days ago
79%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
76%
Momentum
ODDS (%)
Bullish Trend 4 days ago
71%
MACD
ODDS (%)
Bullish Trend 4 days ago
69%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
71%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
71%
Advances
ODDS (%)
Bullish Trend 6 days ago
70%
Declines
ODDS (%)
Bearish Trend 21 days ago
75%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
71%
Aroon
ODDS (%)
Bearish Trend 4 days ago
71%
View a ticker or compare two or three
Ad is loading...
GRFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MFEKX186.941.98
+1.07%
MFS Growth R6
SPGRX17.480.10
+0.58%
DWS Equity Sector Strategy Fund Class S
JHTGX18.410.07
+0.38%
JPMorgan Hedged Equity 3 R5
GVEZX17.93-0.05
-0.28%
GuideStone Funds Value Equity Investor
MMNBX9.37-0.03
-0.32%
MassMutual Diversified Value Y

GIKLY and

Correlation & Price change

A.I.dvisor indicates that over the last year, GIKLY has been closely correlated with GRFS. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if GIKLY jumps, then GRFS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GIKLY
1D Price
Change %
GIKLY100%
N/A
GRFS - GIKLY
68%
Closely correlated
+0.42%
GIFOF - GIKLY
27%
Poorly correlated
N/A
GIFLF - GIKLY
25%
Poorly correlated
N/A
ORINY - GIKLY
9%
Poorly correlated
+3.83%
OPHLY - GIKLY
8%
Poorly correlated
-3.50%
More

GRFS and

Correlation & Price change

A.I.dvisor indicates that over the last year, GRFS has been closely correlated with GIKLY. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if GRFS jumps, then GIKLY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GRFS
1D Price
Change %
GRFS100%
+0.42%
GIKLY - GRFS
68%
Closely correlated
N/A
GIFOF - GRFS
37%
Loosely correlated
N/A
PFE - GRFS
28%
Poorly correlated
+0.61%
BIIB - GRFS
26%
Poorly correlated
-0.56%
GIFLF - GRFS
23%
Poorly correlated
N/A
More